Back to top
more

Halozyme Therapeutics (HALO)

(Real Time Quote from BATS)

$45.65 USD

45.65
206,866

+1.83 (4.18%)

Updated May 15, 2024 11:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

J&J's Darzalex Subcutaneous Version Gets Approval in Europe

by Zacks Equity Research

J&J (JNJ) announces approval of subcutaneous formulation of Darzalex for all current MM indications in first-line as well as relapsed/refractory multiple myeloma.

Zacks.com headshot

ACADIA to Merge Two Phase III Studies on Nuplazid for MDD

by Zacks.com

ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.

argenx Up on Positive Data from Pivotal Efgartigimod Study

by Zacks Equity Research

argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.

Why Halozyme (HALO) Could Be Positioned for a Surge

by Zacks Equity Research

Halozyme (HALO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Why Halozyme (HALO) Stock Might be a Great Pick

by Zacks Equity Research

Halozyme (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Top Ranked Momentum Stocks to Buy for May 15th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 15th

Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Halozyme (HALO) reports wider-than-expected Q1 loss. Shares down.

Halozyme Therapeutics (HALO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -300.00% and -35.57%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Halozyme Therapeutics Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Halozyme Therapeutics

Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Halozyme Therapeutics (HALO) Down 20.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Halozyme Therapeutics (HALO) Stock a Solid Choice Right Now?

by Zacks Equity Research

Halozyme Therapeutics (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance

by Zacks Equity Research

FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.

Surging Earnings Estimates Signal Good News for Halozyme (HALO)

by Zacks Equity Research

Halozyme (HALO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

    Amarin's (AMRN) Q4 Earnings and Sales Surpass Estimates

    by Zacks Equity Research

    Amarin's (AMRN) strong revenue growth in the fourth quarter is driven by solid demand for its cardiovascular drug, Vascepa.

    Halozyme (HALO) Q4 Earnings and Revenues Miss Estimates

    by Zacks Equity Research

    Halozyme (HALO) reports wider-than-expected loss and misses revenue estimates in fourth-quarter 2019. Shares down.

    Halozyme Therapeutics (HALO) Reports Q4 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -33.33% and -2.82%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

    J&J Files Application for Darzalex Label Expansion With FDA

    by Zacks Equity Research

    J&J (JNJ) seeks approval for new Darzalex combo regimen in the United States to treat relapsed/refractory multiple myeloma patients who have received one to three prior lines of therapy.

    Why Is Halozyme Therapeutics (HALO) Up 6.1% Since Last Earnings Report?

    by Zacks Equity Research

    Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Halozyme Therapeutics (HALO) Looks Good: Stock Adds 5.4% in Session

    by Zacks Equity Research

    Halozyme Therapeutics (HALO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

    Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3

    by Zacks Equity Research

    Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.

    Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -41.67% and -21.40%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

    Halozyme Therapeutics (HALO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    by Zacks Equity Research

    Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Roche's New Perjeta Combo Meets Goal in Breast Cancer Study

    by Zacks Equity Research

    Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.

    Halozyme Therapeutics (HALO) Reports Q2 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 41.18% and -0.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?